Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus

Arthritis and Rheumatology

Volumn 67, Issue 1, 2015, Pages 193-203

  Shi, Zhen Rui ^a   Tan, Guo Zhen ^a   Meng, Zhen ^a   Yu, Min ^a   Li, Kai Wen ^a   Yin, Jing ^b   Wei, Kai Hua ^c   Luo, Yi Jin ^a   Jia, Shu Qing ^a   Zhang, Shu Juan ^a   Wu, Jian ^d   Mi, Xiang Bin ^e   Wang, Liangchun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Affiliated Hospital of Shandong Medical Institution   (China)

^c Beijing Proteome Research Center   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 3 ANTIBODY; PROTEIN ANTIBODY; RIBOSOMAL PROTEIN P0; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; GALECTIN 3; HLA ANTIGEN CLASS 2;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DERMATOMYOSITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOBLOTTING; MALE; MASS SPECTROMETRY; PREPUCE; SCLERODERMA; SKIN DEFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; ANIMAL; ANIMAL MODEL; BAGG ALBINO MOUSE; CASE CONTROL STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SKIN; SKIN DISEASE; SYSTEMIC SCLEROSIS; VASCULITIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CASE-CONTROL STUDIES; DERMATOMYOSITIS; FEMALE; GALECTIN 3; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MODELS, ANIMAL; RIBOSOMAL PROTEINS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; SKIN DISEASES; VASCULITIS; YOUNG ADULT;

EID: 84919883414     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38891     Document Type: Article

References (43)

1. Tsokos GC,. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110-21.
2. Rahman A, Isenberg DA,. Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-39.
3. Goldblatt F, O'Neill SG,. Clinical aspects of autoimmune rheumatic diseases. Lancet 2013; 382: 797-808.
4. Font J, Cervera R, Ramos-Casals M, Garcia-Carrasco M, Sents J, Herrero C, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 2004; 33: 217-30.
5. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y,. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004; 34: 501-37.
6. Wahren-Herlenius M, Dorner T,. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013; 382: 819-31.
7. Bizzaro N, Villalta D, Giavarina D, Tozzoli R,. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev 2012; 12: 97-106.
8. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33.
9. Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapaa-Dahlqvist S,. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011; 13: R30.
10. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, the European Working Party on Systemic Lupus Erythematosus. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine (Baltimore) 1993; 72: 113-24.
11. Yell JA, Mbuagbaw J, Burge SM,. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996; 135: 355-62.
12. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
13. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR,. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991; 21: 55-64.
14. Chong BF, Song J, Olsen NJ,. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol 2012; 166: 29-35.
15. Werth VP,. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 2005; 4: 296-302.
16. Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2013; 12: 444-54.
17. Kuhn A, Landmann A,. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun 2014; 48-9: 14-9.
18. Klein RS, Morganroth PA, Werth VP,. Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument. Rheum Dis Clin North Am 2010; 36: 33-51, vii.
19. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
20. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-94.
21. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
23. Meng Z, Shi ZR, Tan GZ, Yin J, Wu J, Mi XB, et al. The association of anti-annexin1 antibodies with the occurrence of skin lesions in systemic lupus erythematosus. Lupus 2014; 23: 183-7.
24. Aden N, Shiwen X, Aden D, Black C, Nuttall A, Denton CP, et al. Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology (Oxford) 2008; 47: 1754-60.
25. Ghirardello A, Doria A, Zampieri S, Gerli R, Rapizzi E, Gambari PF,. Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum Dis 2000; 59: 975-81.
26. Carmona-Fernandes D, Santos MJ, Canhao H, Fonseca JE,. Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile. BMC Med 2013; 11: 98.
27. Li J, Shen Y, He J, Jia R, Wang X, Chen X, et al. Significance of antibodies against the native ribosomal P protein complex and recombinant P0, P1, and P2 proteins in the diagnosis of Chinese patients with systemic lupus erythematosus. J Clin Lab Anal 2013; 27: 87-95.
28. Hirohata S, Kasama T, Kawahito Y, Takabayashi K,. Efficacy of anti-ribosomal P protein antibody testing for diagnosis of systemic lupus erythematosus. Mod Rheumatol 2014. E-pub ahead of print.
29. Ishii K, Washio T, Uechi T, Yoshihama M, Kenmochi N, Tomita M,. Characteristics and clustering of human ribosomal protein genes. BMC Genomics 2006; 7: 37.
30. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B,. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001; 7: 1189-93.
31. Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 2006; 103: 19854-9.
32. Lee JY, Huerta PT, Zhang J, Kowal C, Bertini E, Volpe BT, et al. Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med 2009; 15: 91-6.
33. Ahearn JM, Liu CC, Kao AH, Manzi S,. Biomarkers for systemic lupus erythematosus. Transl Res 2012; 159: 326-42.
34. Rekvig OP, Putterman C, Casu C, Gao HX, Ghirardello A, Mortensen ES, et al. Autoantibodies in lupus: culprits or passive bystanders? Autoimmun Rev 2012; 11: 596-603.
35. Chu P, Pendry K, Blecher TE,. Detection of lupus anticoagulant in patients attending an anticoagulation clinic. BMJ 1988; 297: 1449.
36. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000; 156: 899-909.
37. Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y,. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol 2012; 2012: 606195.
38. Bockle BC, Stanarevic G, Sepp NT,. Detection of Ro/SS-A antibodies in lupus erythematosus: what does it mean for the dermatologist? J Am Acad Dermatol 2013; 68: 385-94.
39. Ioannides D, Golden BD, Buyon JP, Bystryn JC,. Expression of SS-A/Ro and SS-B/La antigens in skin biopsy specimens of patients with photosensitive forms of lupus erythematosus. Arch Dermatol 2000; 136: 340-6.
40. Oke V, Wahren-Herlenius M,. Cutaneous lupus erythematosus: clinical aspects and molecular pathogenesis. J Intern Med 2013; 273: 544-54.
41. Yu C, Chang C, Zhang J,. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review. J Autoimmun 2013; 41: 34-45.
42. Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M,. HMGB1 in systemic lupus erythematosus: its role in cutaneous lesions development. Autoimmun Rev 2010; 9: 661-5.
43. Li PH, Wong WH, Lee TL, Lau CS, Chan TM, Leung AM, et al. Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese. Rheumatology (Oxford) 2013; 52: 337-45.